Table 1.

Clinicopathologic characteristics of patients.

Characteristics	Number of Cases (%)
Age at diagnosis (years)
<40	19 (20%)
40–49	38 (40%)
50–59	18 (18.9%)
>60	20 (21.1%)
Mean	20 (21.1%)
Range	27–74
Pretreatment tumor size (cm)
1–1.9	4 (4.2%)
2–2.9	22 (23.2%)
3–3.9	22 (23.2%)
4–4.9	17 (17.9%)
>4.9	23 (24.2%)
Not measurable	7 (7.4%)
Histological type
Ductal infiltrating	72 (75.8%)
Lobular infiltrating	9 (9.5%)
Inflammatory	6 (6.3%)
Mucinous	6 (6.3%)
Mixed	2 (2.1%)
Histological grade
1	20 (21%)
2	37 (39%)
3	34 (35.8%)
Not evaluable	4 (4.2%)
Clinical TNM at diagnosis
T
T1	6 (6.3%)
T2	62 (65.3%)
T3	16 (16.8%)
T4	8 (8.4%)
Tx	3 (3.2%)
N
N0	34 (35.8%)
N1	46 (48.4%)
N2	15 (15.8%)
N3	0 (0%)
Nx	0 (0%)
M
M0	95 (100%)
M1	0 (0%)
Clinical stage
IIA	32 (33.7%)
IIB	31 (32.6%)
IIIA	21 (21.1%)
IIIB	8 (8.4%)
Not evaluable	3 (3.2%)
ER
≥10%	69 (72.6%)
<10%	25 (26.3%)
Not evaluable	1 (1.1%)
Count ≥ 3	71 (74.7%)
Count < 3	23 (24.2%)
Not evaluable	1 (1.1%)
PR
≥10%	54 (56.8%)
<10%	40 (42.1%)
Not evaluable	1 (1.1%)
Count ≥ 3	58 (61.1%)
Count < 3	36 (37.1%)
Not evaluable	1 (1.1%)
HER2
Positive	20 (21.1%)
Negative	72 (75.8%)
Not evaluable	3 (3.1%)
Ki-67
≥20%	38 (40%)
<20%	56 (58.9%)
Not evaluable	1 (1.1%)
Phenotype
Basal	13 (13.7%)
HER2	20 (21%)
Luminal A	31 (32.6%)
Luminal B	28 (29.5%)
Not evaluable	3 (3.2%)
Type of surgery
Conservative	38 (40%)
Not conservative	56 (58.9%)
Not evaluable	1 (1.1%)
Pathological response (M&P)
Grade 1	8 (8.4%)
Grade 2	22 (23.1%)
Grade 3	28 (29.5%)
Grade 4	17 (17.9%)
Grade 5 (pCR)	20 (21.1%)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.